Home » Stocks » TBPH

Theravance Biopharma, Inc. (TBPH)

Stock Price: $17.05 USD -0.14 (-0.81%)
Updated December 4, 4:00 PM EST - Market closed

TBPH Stock Price Chart

Key Info

Market Cap 1.09B
Revenue (ttm) 82.63M
Net Income (ttm) -285.19M
Shares Out 63.30M
EPS (ttm) -4.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $17.05
Previous Close $17.19
Change ($) -0.14
Change (%) -0.81%
Day's Open 17.19
Day's Range 16.60 - 17.54
Day's Volume 279,498
52-Week Range 14.78 - 31.21

TBPH Stock News

PRNewsWire - 1 month ago

DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization o...

Zacks Investment Research - 3 months ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 3 months ago

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other stocks mentioned: INVA, JAZZ, TXAC, TXG
PRNewsWire - 3 months ago

DUBLIN, Sept. 1, 2020 /PRNewswire/ -- Theravance Biopharma, Inc.

Seeking Alpha - 3 months ago

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.

Zacks Investment Research - 3 months ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.26% and -28.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 3 months ago

DUBLIN, Aug. 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc.

Zacks Investment Research - 4 months ago

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

DUBLIN, July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization o...

PRNewsWire - 5 months ago

DUBLIN, July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the disco...

Zacks Investment Research - 5 months ago

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

PRNewsWire - 5 months ago

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical compa...

Zacks Investment Research - 6 months ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 6 months ago

Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

Seeking Alpha - 6 months ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 7 months ago

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 8 months ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Investors Business Daily - 8 months ago

Theravance Biopharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump T...

Zacks Investment Research - 9 months ago

Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.

Seeking Alpha - 9 months ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.41% and 60.93%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 9 months ago

Investors didn't like the drugmaker's pricing of a planned public stock offering.

Zacks Investment Research - 10 months ago

Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.

The Motley Fool - 10 months ago

Despite achieving several milestones over the past two years, the stock’s response has been muted.

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

InvestorPlace - 1 year ago

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

Other stocks mentioned: ABBV, BIIB, INVA, MYL, NVS, REGN
Seeking Alpha - 1 year ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2019 - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0.00% and -6.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Neil Woodford, the unlucky British fund manager who was yesterday ousted from his flagship fund, is (was) Theravance's largest shareholder.

Zacks Investment Research - 1 year ago

Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.

Seeking Alpha - 1 year ago

Theravance Biopharma has had a 'stealth' 20% rally over the last month despite the recent spike in market volatility.

Zacks Investment Research - 1 year ago

Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.

Seeking Alpha - 1 year ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of 40.98% and 87.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.

Seeking Alpha - 1 year ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of -11.86% and -67.54%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

About TBPH

Theravance Biopharma, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal dis... [Read more...]

Industry
Biotechnology
CEO
Rick Winningham
Employees
316
Stock Exchange
NASDAQ
Ticker Symbol
TBPH
Full Company Profile

Financial Performance

In 2019, TBPH's revenue was $73.41 million, an increase of 21.61% compared to the previous year's $60.37 million. Losses were -$236.46 million, 9.71% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for TBPH is 31.33, which is an increase of 83.75% from the latest price.

Price Target
$31.33
(83.75% upside)